Procept Biorobotics Corp
NASDAQ:PRCT
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
27.89
88.57
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Procept Biorobotics Corp
Free Cash Flow
Procept Biorobotics Corp
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
Procept Biorobotics Corp
NASDAQ:PRCT
|
Free Cash Flow
-$103.6m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Free Cash Flow
$2.7B
|
CAGR 3-Years
17%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
9%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Free Cash Flow
$3.8B
|
CAGR 3-Years
85%
|
CAGR 5-Years
31%
|
CAGR 10-Years
24%
|
|
|
Stryker Corp
NYSE:SYK
|
Free Cash Flow
$4.1B
|
CAGR 3-Years
26%
|
CAGR 5-Years
13%
|
CAGR 10-Years
20%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Free Cash Flow
$6.9B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
9%
|
CAGR 10-Years
12%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Free Cash Flow
$2.3B
|
CAGR 3-Years
28%
|
CAGR 5-Years
18%
|
CAGR 10-Years
15%
|
|
Procept Biorobotics Corp
Glance View
Procept Biorobotics Corp. is a pioneering force in the medical technology landscape, blending innovative engineering with clinical insights to address some of the most pressing challenges in urology. Founded with a vision to revolutionize surgical care, the company developed the AquaBeam Robotic System, an advanced medical platform that leverages robotic precision and real-time ultrasound imaging. This system is primarily employed in performing Aquablation therapy, a minimally invasive treatment designed to alleviate symptoms of benign prostatic hyperplasia (BPH). By integrating robotics and imaging, Procept offers a solution that enhances the accuracy of prostate tissue removal while minimizing risks and downtime for patients—a significant advancement over conventional methods. Revenue generation for Procept Biorobotics centers on the sales of their AquaBeam systems, along with consumables and service contracts that provide ongoing support and upgrades for their hospital and clinical partners. Recognizing the critical nature of procedure efficiency and safety, the company also invests in broadening the application of its technology and frequently seeks endorsements through clinical trials and studies to validate their innovations. By ensuring their cutting-edge solutions meet the stringent demands of healthcare professionals and patients alike, Procept maintains a competitive edge, fostering both adoption and trust within the healthcare community while steadily driving their growth and financial success.
See Also
What is Procept Biorobotics Corp's Free Cash Flow?
Free Cash Flow
-103.6m
USD
Based on the financial report for Dec 31, 2024, Procept Biorobotics Corp's Free Cash Flow amounts to -103.6m USD.
What is Procept Biorobotics Corp's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
-15%
Over the last year, the Free Cash Flow growth was 22%. The average annual Free Cash Flow growth rates for Procept Biorobotics Corp have been -21% over the past three years , -15% over the past five years .